CN1919244B - Chinese traditional medicine for treating cardiovascular disease - Google Patents
Chinese traditional medicine for treating cardiovascular disease Download PDFInfo
- Publication number
- CN1919244B CN1919244B CN2005100148476A CN200510014847A CN1919244B CN 1919244 B CN1919244 B CN 1919244B CN 2005100148476 A CN2005100148476 A CN 2005100148476A CN 200510014847 A CN200510014847 A CN 200510014847A CN 1919244 B CN1919244 B CN 1919244B
- Authority
- CN
- China
- Prior art keywords
- extract
- salviae miltiorrhizae
- radix salviae
- content
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims description 63
- 239000000284 extract Substances 0.000 claims abstract description 114
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 241000208340 Araliaceae Species 0.000 claims abstract description 15
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 15
- 235000008434 ginseng Nutrition 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 14
- 229930182490 saponin Natural products 0.000 claims abstract description 14
- 150000007949 saponins Chemical class 0.000 claims abstract description 14
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 10
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 claims abstract description 9
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 claims abstract description 9
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000017276 Salvia Nutrition 0.000 claims abstract description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 70
- 229930182494 ginsenoside Natural products 0.000 claims description 54
- 229940089161 ginsenoside Drugs 0.000 claims description 54
- 239000011347 resin Substances 0.000 claims description 36
- 229920005989 resin Polymers 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 239000006187 pill Substances 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 22
- 239000003480 eluent Substances 0.000 claims description 19
- 238000010828 elution Methods 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 12
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 11
- 239000012567 medical material Substances 0.000 claims description 11
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 238000011010 flushing procedure Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 238000002844 melting Methods 0.000 claims description 10
- 230000008018 melting Effects 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 229940057995 liquid paraffin Drugs 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 235000009048 phenolic acids Nutrition 0.000 claims description 6
- 150000007965 phenolic acids Chemical class 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 241000521257 Hydrops Species 0.000 claims description 5
- 206010030113 Oedema Diseases 0.000 claims description 5
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 4
- 229920002545 silicone oil Polymers 0.000 claims description 4
- 235000017709 saponins Nutrition 0.000 abstract description 11
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 5
- 235000005412 red sage Nutrition 0.000 abstract description 4
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 abstract 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 239000010669 rosewood oil Substances 0.000 abstract 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- 208000026106 cerebrovascular disease Diseases 0.000 description 9
- 230000002526 effect on cardiovascular system Effects 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 238000004108 freeze drying Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 7
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 7
- 239000012362 glacial acetic acid Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 235000012141 vanillin Nutrition 0.000 description 4
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 4
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 3
- 206010016825 Flushing Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012496 blank sample Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- -1 hydroxypropyl Chemical group 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 101100377706 Escherichia phage T5 A2.2 gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal composition for treating cardiovascular diseases, which is prepared from red sage root extract 60.0-95.0%, ginseng saponin extract 2.5-25.0%, and natural borneol or rosewood oil 2.5-15.0%. The content of danshensu in the salvia miltiorrhizae extract is 3-10%, the content of total savianolic acid is 50-75%, the content of salvianolic acid B is 20-45%, the content of total saponins in ginseng saponin extract is 75-98%. The composition has evident functions in resisting myocardial ischemia, the curative effect is better than the application of single extract of red sage root or ginseng saponin, thus providing a more effective and more convenient Chinese medicinal composition and preparation clinically.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition for the treatment of cardiovascular disease and preparation method thereof.
Background technology
According to China's Epidemiological study, though over nearly 50 years in the rural area or the city, the M ﹠ M of cardiovascular and cerebrovascular disease is all in rising trend.50～sixties, China's population cause of death central vessel disease and cerebrovascular occupied the five or six respectively, then rose to the two or three respectively later in 1975, and cardiovascular and cerebrovascular disease death person has accounted for first of whole disease cause of the death.China accounts for the percentage ratio of total dead population because of cardiovascular and cerebrovascular disease death person, rise to 42.6% of calendar year 2001 by 12.07% of nineteen fifty-seven, the person reaches 2,000,000 though die from the cardiovascular and cerebrovascular disease every year has the part patient to survive through rescue in addition, but majority stays deformity, can't take care of oneself, cause serious burden to relatives and society.Cardiovascular and cerebrovascular disease also is western countries crowd main causes of death.Infer that according to present existing epidemiologic data advancing of disease trend is: to the year two thousand twenty, the human diseases cause of the death puts in order will have great change, but coronary heart disease and apoplexy will be first and second of the human cause of the death.Till that time, estimate that global coronary heart disease death number will increase to 1,100 ten thousand from 6,300,000 of nineteen ninety; Apoplexy increases to 7,700,000 from 4,400,000.Blood circulation cause of the death formation will increase 59.6% in 30 years, and coronary heart disease and apoplexy increase 74.6% and 75% respectively.These data prove absolutely that cardiovascular and cerebrovascular disease is not only the principal disease of harm humans health, especially human " the No.1 killer " who causes death, disables at present and in following 20 years.
In the medicine of cardiovascular and cerebrovascular disease, the application of Chinese medicine and western medicine emphasizes particularly on different fields, and Chinese medicine also occupies the bigger market share with the little advantage of its side effect.In the Chinese patent medicine of present numerous treatment cardiovascular and cerebrovascular diseases, compound red sage root preparation occupies important position, is that the Chinese patent medicine of main active such as Radix Notoginseng total arasaponins, Radix Salviae Miltiorrhizae total phenolic acids, Radix Puerariae flavone, Herb Gynostemmae Pentaphylli total glycosides etc. also more and more is subject to people's attention in addition with effective site.The effect of the various effective ingredient in Chinese of treatment cardiovascular and cerebrovascular disease is had nothing in common with each other and is stressed, the great demand that has drug combination clinically, therefore, the compound red sage root preparation with the effective site preparation will have characteristics such as dosage is little, good effect, steady quality, broad market prospect.
Summary of the invention
The purpose of this invention is to provide little Chinese medicine composition efficiently of a kind of amount and preparation thereof.
Another object of the present invention provides the preparation method of said composition and preparation thereof.
The present invention is implemented by following technical proposals.
Chinese medicine composition of the present invention comprises following component by weight percentage:
Radix Salviae Miltiorrhizae extract 60.0%～95.0%
Ginsenoside extract 2.5%～25.0%
Natural Broneolum Syntheticum or Lignum Dalbergiae Odoriferae oil 2.5%～15.0%
Chinese medicine composition of the present invention more preferably comprises following component by weight percentage:
Radix Salviae Miltiorrhizae extract 75.0%～90.0%,
Ginsenoside extract 6.0%～15.0%,
Natural Broneolum Syntheticum or Lignum Dalbergiae Odoriferae oil 4.0%～10.0%;
Chinese medicine composition of the present invention, best for comprising following component by weight percentage:
Radix Salviae Miltiorrhizae extract 80%,
Ginsenoside extract 13%,
Natural Broneolum Syntheticum or Lignum Dalbergiae Odoriferae oil 7%;
Above-mentioned Radix Salviae Miltiorrhizae extract obtains with following method: get the Radix Salviae Miltiorrhizae of salvia piece or pulverizing, decoct with water or supersound extraction 2～3 times, add 5～7 times of water gagings of medical material weight, each 0.5～2 hour at every turn; Merge extractive liquid, is 1.5～4 with acid for adjusting pH, puts coldly, filters; The resin volume is equivalent to the macroporous resin column of 2～4 times of crude drugs on the filtrate, and with 1～1.5 times of cylinder hydrops flushing, water lotion discards earlier, and 85～95% ethanol elutions of 2～3 times of column volumes of reuse are collected eluent; The eluent concentrating under reduced pressure, drying promptly gets Radix Salviae Miltiorrhizae extract.The content of Danshensu of this Radix Salviae Miltiorrhizae extract is 3%～10%, and Radix Salviae Miltiorrhizae total phenolic acids content is 50%～75%, and content of danshinolic acid B is 20%～45%.
Above-mentioned macroporous resin is the macroporous resin of nonpolar or low pole, is preferably D101, AB-8 or ZTC type macroporous resin, and the best is an AB-8 type macroporous resin.
Above-mentioned content of Danshensu assay method is referring to Chinese patent CN1520307A, and Radix Salviae Miltiorrhizae total phenolic acids assay and content of danshinolic acid B are measured referring to Chinese patent CN1600318A.
Above-mentioned ginsenoside extract can obtain with following method: get the ginseng crude drug, pulverize, add 5～8 times of amounts of medical material weight, 50～90% ethanol, reflux or supersound extraction 2～3 times, merge extractive liquid; Extracting solution filters, and being concentrated into does not have the alcohol flavor, is dissolved in water, and filters; Macroporous resin column on the filtrate with the water flushing of 2～4 times of amount column volumes, is used 60～85% ethanol elutions of 2～4 column volumes then, collects ethanol elution, the eluent concentrating under reduced pressure, and drying promptly gets ginsenoside extract.The Radix Ginseng total saponins content of this ginsenoside extract is 75%～98%.
Above-mentioned macroporous resin is the macroporous resin of nonpolar or low pole, is preferably D101, AB-8 or ZTC type macroporous resin, and the best is an AB-8 type macroporous resin.
Ginsenoside extract also is commercially available, as long as Radix Ginseng total saponins content is 75%～98%.
Above-mentioned Radix Ginseng total saponins content (in the ginsenoside Re) assay method is as follows:
1. instrument and reagent
1.1 instrument
Ultraviolet-uisible spectrophotometer.Chromatographic column.
1.2 standard substance, test sample and reagent
Standard substance: ginsenoside Re: Nat'l Pharmaceutical ﹠ Biological Products Control Institute
Test sample: ginsenoside extract
Reagent: AB-8 macroporous resin or G..D.X-101 macroporous resin (60～80 orders, Tianjin chemical reagent two factories)
The ethanol analytical pure
Vanillin solution takes by weighing the 5g vanillin, and the ice acetic acid dissolving also is settled to 100ml.
The perchloric acid analytical pure
The glacial acetic acid analytical pure
Ginsenoside Re's standard solution: precision takes by weighing ginsenoside Re's standard substance 0.0100g, and with dissolve with methanol and be settled to 10ml, promptly every milliliter contains ginsenoside Re 1.0mg.
2. experiment
2.1 sample treatment: get the 2mg ginsenoside extract, with certain water gaging dilution (being diluted to about 50ml).
2.2 column chromatography: make the chromatography pipe with the 10mL syringe, interior dress 4cm AB-8 macroporous resin is washed post with 20mL95% ethanol earlier, discards eluent, and reuse 25mL washes post, discards eluent.The accurate sample solution of having handled well (seeing 2.1) that adds, flow speed control is about 1mL/min.Earlier wash post with 15mL, discard eluent, reuse 20mL95% ethanol elution arasaponin is collected eluent in evaporating dish, places 75 ℃ of water-baths to volatilize.Doing colour developing with this uses.
2.3 the preparation of blank sample: in clean evaporating dish, accurately add 0.2mL5% vanillin glacial acetic acid solution, rotate evaporating dish, residue is all dissolved, add 0.8mL perchloric acid again, move into behind the mixing in the 10mL band plug graduated centrifuge tube; Add the 0.2mL glacial acetic acid in the evaporating dish again, rotate evaporating dish, make the residual liquid dissolving, move into again in the above-mentioned centrifuge tube, heat 10min in 60 ℃ of water-baths, take out, after the ice bath cooling, accurately add glacial acetic acid 5.0mL, after shaking up, promptly get blank sample.
2.4 colour developing: in the above-mentioned evaporating dish that has volatilized, accurately add 0.2mL5% vanillin glacial acetic acid solution, rotate evaporating dish, residue is all dissolved, add 0.8mL perchloric acid again, move into behind the mixing in the 10mL band plug graduated centrifuge tube; Add the 0.2mL glacial acetic acid in the evaporating dish again, rotate evaporating dish, make the residual liquid dissolving, move into again in the above-mentioned centrifuge tube, heat 10min in 60 ℃ of water-baths, take out, after the ice bath cooling, accurately add glacial acetic acid 5.0mL, after shaking up, carry out colorimetric determination (after with blank sample ultraviolet-uisible spectrophotometer being returned zero, measuring again) with standard pipe in 560nm wavelength place with the 1cm colorimetric pool.
2.5 standard pipe: draw ginsenoside Re's standard solution (1.0mg/mL) 0.1mL, with certain water gaging dilution (about 10ml), below operate from " A2.2 column chromatography ... " rise, identical with sample, measure absorbance.
3 calculate:
C sample=(A1 * C mark * 100)/(A2 * 6)
In the formula:
C sample: the amount of Radix Ginseng total saponins (in the ginsenoside Re) in the extract, mg/100mL
A1: the absorbance of test solution,
A
2: the absorbance of titer,
C
Mark: the concentration of titer, mg/mL
Result of calculation keeps three position effective digitals.
Natural Broneolum Syntheticum in the above-mentioned Chinese medicine composition should meet the Chinese Pharmacopoeia standard.Natural Broneolum Syntheticum can replace with the Borneolum Syntheticum that meets the Chinese Pharmacopoeia standard.
Lignum Dalbergiae Odoriferae oil in the above-mentioned Chinese medicine composition is that the Lignum Dalbergiae Odoriferae medical material is through the distillation gained.
Effective ingredient in Chinese compositions of the present invention, the various dosage forms that can be mixed and made into adjuvant on any or more than one pharmaceuticss such as starch, dextrin, lactose, microcrystalline Cellulose, hydroxypropyl methylcellulose, Polyethylene Glycol, magnesium stearate, micropowder silica gel, xylitol, lactose, glucose, glycine, mannitol, glycine etc., for example, can be made into aqueous injection, tablet, slow releasing tablet, drop pill, granule, injectable powder, capsule, microgranule.Preferred dosage form is drop pill, injectable powder.
The preparation of Chinese medicine composition composition dropping pills of the present invention: get above-mentioned Radix Salviae Miltiorrhizae extract, ginsenoside extract and natural Broneolum Syntheticum (or Lignum Dalbergiae Odoriferae oil) to scale, Polyethylene Glycol-6000 or Polyethylene Glycol-4000 or both mixture mix homogeneously with 2～4 times of medicine gross weights, heating and melting, move in the dropping-pill machine jar after changing material, in medicine liquid droplet to 6～8 ℃ liquid paraffin or the methyl-silicone oil, oil removing, promptly.
The preparation of Chinese medicine composition injectable powder of the present invention: get above-mentioned Radix Salviae Miltiorrhizae extract, ginsenoside extract and natural Broneolum Syntheticum to scale, add an amount of adjuvant and distilled water, the mixing postlyophilization, promptly.
Chinese medicine composition raw material sources of the present invention are easy to get, and are easy to industrialization; Can make various dosage forms as required, for clinical provide convenient, more effectively, the more controlled modern Chinese medicine of quality, for the patient brings more benefits, thereby produce the huge social benefit.
The present invention adopts rat experiment myocardial infarction model and external perfusion method, has compared the function of resisting myocardial ischemia of Chinese medicine composition of the present invention, Radix Salviae Miltiorrhizae extract, ginsenoside extract.The result shows that Chinese medicine composition of the present invention has tangible function of resisting myocardial ischemia, and its curative effect is better than using Radix Salviae Miltiorrhizae extract or ginsenoside extract separately, shows that Chinese medicine composition of the present invention has stronger synergism.
The experimentation of several Chinese medicine extract function of resisting myocardial ischemia of experimental example
1, grouping and administration
70 of Wister male rats, body weight 250.8 ± 24.6 is divided into 7 groups at random by body weight: the normal saline matched group; The Radix Salviae Miltiorrhizae extract group of embodiment one; The ginsenoside extract group of embodiment one; Embodiment one Chinese medicine composition; Embodiment two Chinese medicine compositions.Each medicine all is diluted to desired concn with normal saline, and dosage is 4ml/kg, the tail intravenously administrable.
2, method
(1), rat experiment myocardial infarction model: animal pentobarbital sodium intraperitoneal injection of anesthesia (45mg/kg), it is fixing to face upward the position.Tracheal intubation is made the longitudinal incision of 2cm in breastbone left side, nearly breastbone side is cut off the 3rd, the 4th and reined in cartilage, open the thoracic cavity after, connect artificial respirator (ventilation 2ml/100g, 50 times/min).Cut off pericardium, expose heart, left anterior descending coronary artery root threading is in order to ligation, and record standard II lead electrocardiogram was stablized 10 minutes, and the ligation left anterior descending coronary artery is closed the thoracic cavity.With syringe sucking-off animal throat secretions, make animal recover autonomous respiration.Behind the ligation coronary artery 15min, intravenously administrable.Behind the ligation coronary artery 4 hours, win heart, 5 of the following crosscuts of ligature, carry out chlorination nitro blue tetrazolium (NBT) dyeing, calculating myocardium infarcted region area accounts for the percentage ratio of ventricle and heart area, and carries out statistical procedures (t check).
(2), stripped langendorff heart perfusion: carry out with reference to the pharmacological experimental methodology third edition.
3, result
(1), to the influence of rat experiment myocardial inyaretion scope, the results are shown in Table 1.
The various extracts of table 1 are to the influence of rat experiment myocardial inyaretion scope (x ± s)
Annotate: compare * P＜0.05, * * P＜0.01 with model group; Compare with the Radix Salviae Miltiorrhizae extract group,
#P＜0.05,
##P＜0.01; Compare with the ginsenoside extract group,
﹠amp;P＜0.05,
﹠amp; ﹠amp;P＜0.01
(2), to the influence of dirty coronary flow of guinea-pig heart and heart rate, the results are shown in Table 2.
The various extracts of table 2 are to the influence of dirty coronary flow of guinea-pig heart and heart rate (x ± s)
Annotate: compare * P＜0.05, * * P＜0.01 with the Radix Salviae Miltiorrhizae extract group; Compare with the ginsenoside extract group,
#P＜0.05,
##P＜0.01.
The result of above table 1 and table 2 shows that each administration group all has tangible function of resisting myocardial ischemia, and the curative effect of the present composition is best.
The specific embodiment
To be easier to understand the present invention with reference to the following example, and provide embodiment and be in order to illustrate the present invention, rather than in order to limit the scope of the invention.
Embodiment one
The preparation of Radix Salviae Miltiorrhizae extract: get the Radix Salviae Miltiorrhizae of salvia piece or pulverizing, decoct with water 2 times, add 6.5 times of water gagings of medical material weight, each 2 hours at every turn; Merge extractive liquid, is 2 with acid for adjusting pH, puts coldly, filters; The resin volume is equivalent to AB-8 type macroporous resin (production of Tianjin resin processing plant of the Nankai University) post of 3 times of crude drugs on the filtrate, and with 1.5 times of cylinder hydrops flushings, water lotion discards earlier, and 95% ethanol elution of 2.5 times of column volumes of reuse is collected eluent; Eluent is evaporated to extractum proportion 1.15, and drying under reduced pressure promptly gets Radix Salviae Miltiorrhizae extract.The content of Danshensu 4.5% of this Radix Salviae Miltiorrhizae extract, total phenolic content 57.1%, content of danshinolic acid B 27.5%.
The preparation of ginsenoside extract: get the ginseng crude drug, pulverize, add 7 times of amounts of medical material weight, 70% ethanol, heating and refluxing extraction 2 times, merge extractive liquid; Extracting solution filters, and being concentrated into does not have the alcohol flavor, is dissolved in water, and filters; AB-8 type macroporous resin on the filtrate (production of Tianjin resin processing plant of Nankai University) post with the water flushing of 3 times of amount column volumes, is used 75% ethanol elution of 3 column volumes then, collects ethanol elution, the eluent concentrating under reduced pressure, and vacuum drying promptly gets ginsenoside extract.The Radix Ginseng total saponins content 82.3% of this ginsenoside extract.
Get above-mentioned Radix Salviae Miltiorrhizae extract 5.6g, above-mentioned ginsenoside extract 0.9g, natural Broneolum Syntheticum 0.5g, mix homogeneously, lyophilization gets Chinese medicine composition.
Embodiment two
The preparation of Radix Salviae Miltiorrhizae extract: get the Radix Salviae Miltiorrhizae of salvia piece or pulverizing, add the water supersound extraction 2 times, add 6 times of water gagings of medical material weight, each 40 minutes at every turn; Merge extractive liquid, is 2.5 with acid for adjusting pH, puts coldly, filters; The resin volume is equivalent to D101 type macroporous resin (production of Tianjin resin processing plant of the Nankai University) post of 3 times of crude drugs on the filtrate, and with 1.0 times of cylinder hydrops flushings, water lotion discards earlier, and 95% ethanol elution of 3 times of column volumes of reuse is collected eluent; Eluent is evaporated to extractum proportion 1.15, and drying under reduced pressure promptly gets Radix Salviae Miltiorrhizae extract.The content of Danshensu 4.6% of this Radix Salviae Miltiorrhizae extract, total phenolic content 54.6%, content of danshinolic acid B 26.4%.
The preparation of ginsenoside extract: get the ginseng crude drug, pulverize, add 6.5 times of amounts of medical material weight, 65% ethanol, supersound extraction 2 times, merge extractive liquid; Extracting solution filters, and being concentrated into does not have the alcohol flavor, is dissolved in water, and filters; D101 type macroporous resin on the filtrate (production of Tianjin resin processing plant of Nankai University) post with the water flushing of 3 times of amount column volumes, is used 75% ethanol elution of 3 column volumes then, collects ethanol elution, the eluent concentrating under reduced pressure, and lyophilization promptly gets ginsenoside extract.The Radix Ginseng total saponins content 81.9% of this ginsenoside extract.
Get above-mentioned Radix Salviae Miltiorrhizae extract 5.6g, above-mentioned ginsenoside extract 0.9g, Lignum Dalbergiae Odoriferae oil 0.5g, add 9.0g Polyethylene Glycol-6000 mix homogeneously, fusion gets Chinese medicine composition after the cooling.
Embodiment three
The preparation of Radix Salviae Miltiorrhizae extract: get the Radix Salviae Miltiorrhizae of salvia piece or pulverizing, decoct with water 2 times, add 6.5 times of water gagings of medical material weight, each 2 hours at every turn; Merge extractive liquid, is 2 with acid for adjusting pH, puts coldly, filters; The resin volume is equivalent to ZTC type macroporous resin (production of Tianjin resin processing plant of the Nankai University) post of 3 times of crude drugs on the filtrate, and with 1.5 times of cylinder hydrops flushings, water lotion discards earlier, and 95% ethanol elution of 2.5 times of column volumes of reuse is collected eluent; Eluent is evaporated to extractum proportion 1.12, and drying under reduced pressure promptly gets Radix Salviae Miltiorrhizae extract.The content of Danshensu 4.1% of this Radix Salviae Miltiorrhizae extract, total phenolic content 53.6%, content of danshinolic acid B 24.8%.
The preparation of ginsenoside extract: get the ginseng crude drug, pulverize, add 7 times of amounts of medical material weight, 75% ethanol, heating and refluxing extraction 2 times, merge extractive liquid; Extracting solution filters, and being concentrated into does not have the alcohol flavor, is dissolved in water, and filters; ZTC type macroporous resin on the filtrate (production of Tianjin resin processing plant of Nankai University) post with the water flushing of 3 times of amount column volumes, is used 75% ethanol elution of 3 column volumes then, collects ethanol elution, the eluent concentrating under reduced pressure, and vacuum drying promptly gets ginsenoside extract.The Radix Ginseng total saponins content 82.6% of this ginsenoside extract.
Get above-mentioned Radix Salviae Miltiorrhizae extract 6.8g, above-mentioned ginsenoside extract 0.8g, natural Broneolum Syntheticum 0.5g, mix homogeneously, lyophilization gets Chinese medicine composition.
Embodiment four
Get ginsenoside extract 1.0g, the natural Broneolum Syntheticum 0.4g of Radix Salviae Miltiorrhizae extract 5.7g, the embodiment two of embodiment one, mix homogeneously, lyophilization gets Chinese medicine composition.
Embodiment five
Get ginsenoside extract 0.8g, the Borneolum Syntheticum 0.5g of Radix Salviae Miltiorrhizae extract 5.1g, the embodiment three of embodiment one, mix homogeneously, lyophilization gets Chinese medicine composition.
Embodiment six
Get ginsenoside extract 0.8g, the Lignum Dalbergiae Odoriferae oil 0.4g of Radix Salviae Miltiorrhizae extract 8.9g, the embodiment two of embodiment two, add 12.0g Polyethylene Glycol-6000 mix homogeneously, fusion gets Chinese medicine composition after the cooling.
Embodiment seven
Get ginsenoside extract 0.9g, the natural Broneolum Syntheticum 0.5g of Radix Salviae Miltiorrhizae extract 5.6g, the embodiment one of embodiment one, with 18.5g Polyethylene Glycol-6000 mix homogeneously, heating and melting, move in the dropping-pill machine jar after changing material, in ℃ liquid paraffin of medicine liquid droplet to 6～8, oil removing makes 1000 of drop pill.
Embodiment eight
Get ginsenoside extract 0.8g, the natural Broneolum Syntheticum 0.5g of Radix Salviae Miltiorrhizae extract 6.2g, the embodiment two of embodiment two, with 18.0g Polyethylene Glycol-4000 mix homogeneously, heating and melting, move in the dropping-pill machine jar after changing material, in ℃ liquid paraffin of medicine liquid droplet to 6～8, oil removing makes 1000 of drop pill.
Embodiment nine
Get ginsenoside extract 1.0g, the natural Broneolum Syntheticum 0.5g of Radix Salviae Miltiorrhizae extract 5.2g, the embodiment one of embodiment three, with 19.0g Polyethylene Glycol-6000 mix homogeneously, heating and melting, move in the dropping-pill machine jar after changing material, in ℃ methyl-silicone oil of medicine liquid droplet to 6～8, oil removing makes 1000 of drop pill.
Embodiment ten
Get ginsenoside extract 0.9g, the natural Broneolum Syntheticum 0.5g of Radix Salviae Miltiorrhizae extract 6.8g, the embodiment two of embodiment one, with 3.5g Polyethylene Glycol-4000 and 14.0g Polyethylene Glycol-6000 mix homogeneously, heating and melting, move in the dropping-pill machine jar after changing material, in ℃ liquid paraffin of medicine liquid droplet to 6～8, oil removing makes 1000 of drop pill.
Embodiment 11
Get ginsenoside extract 0.8g, the natural Broneolum Syntheticum 0.5g of Radix Salviae Miltiorrhizae extract 7.9g, the embodiment one of embodiment three, with 16.5g Polyethylene Glycol-6000 mix homogeneously, heating and melting, move in the dropping-pill machine jar after changing material, in ℃ liquid paraffin of medicine liquid droplet to 6～8, oil removing makes 1000 of drop pill.
Embodiment 12
Get ginsenoside extract 0.8g, the Borneolum Syntheticum 0.4g of Radix Salviae Miltiorrhizae extract 6.5g, the embodiment two of embodiment three, with 17.5g Polyethylene Glycol-6000 mix homogeneously, heating and melting, move in the dropping-pill machine jar after changing material, in ℃ liquid paraffin of medicine liquid droplet to 6～8, oil removing makes 1000 of drop pill.
Embodiment 13
Get ginsenoside extract 0.9g, the Lignum Dalbergiae Odoriferae oil 0.5g of Radix Salviae Miltiorrhizae extract 5.6g, the embodiment one of embodiment one, with 18.5g Polyethylene Glycol-6000 mix homogeneously, heating and melting, move in the dropping-pill machine jar after changing material, in ℃ methyl-silicone oil of medicine liquid droplet to 6～8, oil removing makes 1000 of drop pill.
Embodiment 14
Get ginsenoside extract 0.8g, the Lignum Dalbergiae Odoriferae oil 0.5g of Radix Salviae Miltiorrhizae extract 6.2g, the embodiment two of embodiment two, with 3.5g Polyethylene Glycol-4000 and 14.5g Polyethylene Glycol-6000 mix homogeneously, heating and melting, move in the dropping-pill machine jar after changing material, in ℃ liquid paraffin of medicine liquid droplet to 6～8, oil removing makes 1000 of drop pill.
Embodiment 15
Get ginsenoside extract 2.5g, natural Broneolum Syntheticum 1.2g, mannitol 5.5g, calcium disodium edetate 0.9g and the distilled water 1ml of Radix Salviae Miltiorrhizae extract 16.4g, the embodiment one of embodiment one, behind the said components mixing, lyophilization, 1000 of packing, promptly.
Embodiment 16
Get ginsenoside extract 2.9g, natural Broneolum Syntheticum 1.2g, low molecular dextran 5.5g, calcium disodium edetate 0.9g and the distilled water 1ml of Radix Salviae Miltiorrhizae extract 15.7g, the embodiment two of embodiment two, behind the said components mixing, lyophilization, 1000 of packing, promptly.
Embodiment 17
Get ginsenoside extract 1.9g, Borneolum Syntheticum 1.2g, glucose 5.5g, sodium thiosulfate 0.9g and the distilled water 1ml of Radix Salviae Miltiorrhizae extract 16.7g, the embodiment one of embodiment three, behind the said components mixing, lyophilization, 1000 of packing, promptly.
Embodiment 18
Get Lignum Dalbergiae Odoriferae oil 1.5g, join in the saturated hydroxypropyl solution of 13ml, stirring and dissolving filters, the filtrate cold drying, the clathrate powder of Lignum Dalbergiae Odoriferae oil and hydroxypropyl.Except that the clathrate powder of above-mentioned Lignum Dalbergiae Odoriferae oil and hydroxypropyl, get ginsenoside extract 2.5g, mannitol 5.5g, calcium disodium edetate 0.9g and the distilled water 2ml of Radix Salviae Miltiorrhizae extract 16.4g, the embodiment one of embodiment one again, behind the said components mixing, lyophilization, 1000 of packing, promptly.
Embodiment 19
Get ginsenoside extract 1.2g, the Borneolum Syntheticum 0.8g of Radix Salviae Miltiorrhizae extract 12.5g, the embodiment one of embodiment one, with 210g microcrystalline Cellulose mix homogeneously, add 3% polyvidone alcoholic solution system soft material, cross 18 mesh sieve system granules, 60 ℃ of dryings 30～45 minutes, granulate, add the 24g Pulvis Talci, mixing fills in 1000 capsules, promptly.
Embodiment 20
Get ginsenoside extract 1.2g, the natural Broneolum Syntheticum 0.8g of Radix Salviae Miltiorrhizae extract 12.5g, the embodiment two of embodiment one,, be pressed into 1000, promptly with 64g microcrystalline Cellulose and 20g magnesium stearate mix homogeneously.
Claims (9)
1. Chinese medicine composition for the treatment of cardiovascular disease, form by following component by weight percentage:
Radix Salviae Miltiorrhizae extract 60.0%～95.0%,
Ginsenoside extract 2.5%～25.0%,
Natural Broneolum Syntheticum or Lignum Dalbergiae Odoriferae oil 2.5%～15.0%;
Described Radix Salviae Miltiorrhizae extract is prepared by following method:
Get the Radix Salviae Miltiorrhizae of salvia piece or pulverizing, decoct with water or supersound extraction 2～3 times, add 5～7 times of water gagings of medical material weight, each 0.5～2 hour at every turn; Merge extractive liquid, is 1.5～4 with acid for adjusting pH, puts coldly, filters; The resin volume is equivalent to the macroporous resin column of 2～4 times of crude drugs on the filtrate, and with 1～1.5 times of cylinder hydrops flushing, water lotion discards earlier, and 85～95% ethanol elutions of 2～3 times of column volumes of reuse are collected eluent; The eluent concentrating under reduced pressure, drying promptly gets Radix Salviae Miltiorrhizae extract;
Content of Danshensu in the described Radix Salviae Miltiorrhizae extract is 3%～10%, and Radix Salviae Miltiorrhizae total phenolic acids content is 50%～75%, and content of danshinolic acid B is 20%～45%; The total saponin content of ginsenoside extract is 75%～98%.
2. according to the described Chinese medicine composition of claim 1, it is characterized in that the percentage by weight of described each component is:
Radix Salviae Miltiorrhizae extract 75.0%～90.0%,
Ginsenoside extract 6.0%～15.0%,
Natural Broneolum Syntheticum or Lignum Dalbergiae Odoriferae oil 4.0%～10.0%;
Wherein the content of Danshensu of Radix Salviae Miltiorrhizae extract is 3%～10%, and Radix Salviae Miltiorrhizae total phenolic acids content is 50%～75%, and content of danshinolic acid B is 20%～45%; The total saponin content of ginsenoside extract is 75%～98%.
3. according to the described Chinese medicine composition of claim 1, it is characterized in that the percentage by weight of described each component is:
Radix Salviae Miltiorrhizae extract 80%,
Ginsenoside extract 13%,
Natural Broneolum Syntheticum or Lignum Dalbergiae Odoriferae oil 7%;
Wherein the content of Danshensu of Radix Salviae Miltiorrhizae extract is 3%～10%, and Radix Salviae Miltiorrhizae total phenolic acids content is 50%～75%, and content of danshinolic acid B is 20%～45%; The total saponin content of ginsenoside extract is 75%～98%.
4. Chinese medicine composition according to claim 1 is characterized in that, described macroporous resin is D101, AB-8 or ZTC type macroporous resin.
5. according to the described Chinese medicine composition of the arbitrary claim of claim 1～3, it is characterized in that described ginsenoside extract is prepared by following method: get the ginseng crude drug, pulverize, add 5～8 times of amounts of medical material weight, 50～90% ethanol, reflux or supersound extraction 2～3 times, merge extractive liquid; Extracting solution filters, and being concentrated into does not have the alcohol flavor, is dissolved in water, and filters; Macroporous resin column on the filtrate with the water flushing of 2～4 times of amount column volumes, with 60～85% ethanol elutions of 2～4 times of amount column volumes, is collected ethanol elution then, the eluent concentrating under reduced pressure, and drying promptly gets ginsenoside extract.
6. Chinese medicine composition according to claim 5 is characterized in that, described macroporous resin is D101, AB-8 or ZTC type macroporous resin.
7. be the preparation that active component is made according to the described Chinese medicine composition of the arbitrary claim of claim 1～3.
8. be the drop pill that active component is made according to the described Chinese medicine composition of the arbitrary claim of claim 1～3, it is characterized in that, described drop pill is prepared from by following method: get above-mentioned Radix Salviae Miltiorrhizae extract, ginsenoside extract and natural Broneolum Syntheticum or Lignum Dalbergiae Odoriferae oil to scale, Polyethylene Glycol-6000 or Polyethylene Glycol-4000 or both mixture mix homogeneously with 2～4 times of medicine gross weights, heating and melting, move in the dropping-pill machine jar after changing material, in medicine liquid droplet to 6～8 ℃ liquid paraffin or the methyl-silicone oil, oil removing, promptly.
9. be the injectable powder that active component is made according to the described Chinese medicine composition of the arbitrary claim of claim 1～3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100148476A CN1919244B (en) | 2005-08-24 | 2005-08-24 | Chinese traditional medicine for treating cardiovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100148476A CN1919244B (en) | 2005-08-24 | 2005-08-24 | Chinese traditional medicine for treating cardiovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1919244A CN1919244A (en) | 2007-02-28 |
| CN1919244B true CN1919244B (en) | 2011-04-27 |
Family
ID=37777180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005100148476A Expired - Fee Related CN1919244B (en) | 2005-08-24 | 2005-08-24 | Chinese traditional medicine for treating cardiovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1919244B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168844A (en) * | 2015-10-28 | 2015-12-23 | 青岛金智高新技术有限公司 | Medicine for treating portal hypertension postoperative treating thrombosis |
| CN105267535A (en) * | 2015-11-20 | 2016-01-27 | 青岛金智高新技术有限公司 | Medicine for prevention and treatment of postoperative lower extremity deep venous thrombosis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1349818A (en) * | 2001-10-24 | 2002-05-22 | 沈阳药科大学 | Effective part group in red sage mixture and its delayed release prepn. medicinal use and prepn process |
-
2005
- 2005-08-24 CN CN2005100148476A patent/CN1919244B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1349818A (en) * | 2001-10-24 | 2002-05-22 | 沈阳药科大学 | Effective part group in red sage mixture and its delayed release prepn. medicinal use and prepn process |
Non-Patent Citations (1)
| Title |
|---|
| 国家药品监督管理局.国家中成药标准汇编 中成药地方标准上升国家标准 内科 心系分册.2002,369页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1919244A (en) | 2007-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100404035C (en) | Combination of Chinese traditional medicine for curing cardiovascular diseases and cerebrovascular disease | |
| US7314644B2 (en) | Extraction and purification method of active constituents from stem of Lonicera japonica thunb., its usage for anti-inflammatory and analgesic drug | |
| CN104644658A (en) | Application of ginsenoside Rg3 in preparation of medicine for relieving and/or treating dementia disease and medicine | |
| CN105078956A (en) | Application of forsythin aglycone in preparing medicine for preventing or treating liver injury or liver failure | |
| CN1919248B (en) | Traditional Chinese medicinal formulation for treating cardiovascular and cerebrovascular disease | |
| CN1919240B (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases | |
| CN104352624A (en) | Application of Mongolian medicine Cymbaria n-butanol extract in preparation of medicine for preventing and curing diabetes | |
| CN1919239B (en) | Traditional medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN100415255C (en) | Composition of Chinese traditional medicine, and preparation method | |
| CN102614230A (en) | Medicinal composition for treating rheumatoid arthritis and preparation method and application thereof | |
| CN1919244B (en) | Chinese traditional medicine for treating cardiovascular disease | |
| CN1919238B (en) | Medicine for treating cardiovascular and cerebrovascular disease | |
| CN1919252B (en) | Medicine for treating cardiovascular and cerebrovascular disease | |
| CN1919247B (en) | Chinese medicine for treating cardiovascular and cerebrovascular disease | |
| CN100467025C (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN1919249B (en) | Chinese traditional medicine for treating cardiovascular and cerebrovascular disease | |
| CN1919242B (en) | Traditional Chinese medicine composition for treating cardiac and cerebral vascular disease | |
| CN102743374A (en) | Application of bellidifolin in preparation of drugs for prevention and treatment of cardiacarrhythmia | |
| CN1919251B (en) | Traditional Chinese medicine composition for treating cardiac vascular disease | |
| CN1919237B (en) | Medicine for treating cardiovascular and cerebrovascular diseases | |
| CN1919245B (en) | Traditional medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN1919235B (en) | Cardiac and cerebral vascular disease treating pharmaceutical composition | |
| CN101073598B (en) | Medicinal composition for treating cardiovascular and cerebrovascular disease and its preparation | |
| CN1919246B (en) | Traditional Chinese medicine for treating cardiovascular diseases | |
| CN1919236B (en) | Medicine for treating cardiovascular and cerebrovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070608 Address after: Tianjin City Hedong District of Beichen Puji No. 2 in the modern Chinese medicine city Applicant after: Tianjin Tianshili Pharmaceutical Co., Ltd. Address before: The white road of Beichen science and Technology Park in Beichen District of Tianjin City Xinyi Liaohe Road No. 1 Applicant before: Tianshili Modern Traditional Chinese Medicine Research & Devleopment Co., Ltd., |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin city Beichen District Puji Hedong No. 2 in the modern Chinese medicine city Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin city Beichen District Puji Hedong No. 2 in the modern Chinese medicine city Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin city Beichen District Puji Hedong No. 2 in the modern Chinese medicine city Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin city Beichen District Puji Hedong No. 2 in the modern Chinese medicine city Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110427 Termination date: 20190824 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |